Sign in Subscribe
Pharmaceutical industry

Immunotherapy-Related Pneumonitis in Cancer Patients Continues to Pose Challenges

Strategic Insights

— 1 min read

Researchers have reported two cases of cancer patients experiencing pneumonitis, a severe and potentially life-threatening side effect, while undergoing immunotherapy with anti-programmed cell death 1 (PD-1) inhibitors. Despite the discontinuation of immunotherapy, both patients remained in complete remission for over a year. This study highlights the ongoing challenges and risks associated with immune checkpoint inhibition (ICI) and underscores the importance of careful patient monitoring and management.

Key Takeaways:

  • The study reported two cases of grade III dyspnea due to pneumonitis in cancer patients treated with anti-PD-1 inhibitors, which is a rare but severe side effect of immunotherapy.
  • Both patients required treatment with systemic corticosteroids after immunotherapy was discontinued, but they continued to experience complete remission for over a year.
  • The study emphasizes the need for careful patient monitoring and management in cases of immune-related pneumonitis, particularly in patients receiving ICI therapy.
  • The researchers note that their findings align with recent literature reports on immune-related pneumonitis and the persistence of response beyond discontinuation.
  • Financial supporters for the research include major pharmaceutical companies such as Bristol-Myers Squibb, Roche, AstraZeneca, Sanofi, and Novartis.
  • The study provides valuable insights into the challenges and risks associated with ICI therapy and highlights the importance of continued research in this field.

Statistics:

  • The two patients reported in the study were treated with anti-PD-1 inhibitors and experienced grade III dyspnea due to pneumonitis.
  • Both patients required treatment with systemic corticosteroids after immunotherapy was discontinued.
  • The patients remained in complete remission for over 1 year after immunotherapy was discontinued.
  • The study notes that ICI therapy has become increasingly common in cancer treatment, with a correlating increase in the risk of immune-related adverse events (irAEs).
  • The financial supporters for the research include major pharmaceutical companies that develop and market ICI therapies.

Sources:

  • Persistent Anti-tumor Response In Cancer Patients Experiencing Pneumonitis Related To Immune Checkpoint Blockade. Acta Clinica Belgica, 2021;76(2):144-148. Acta Clinica Belgica can be contacted at: Taylor & Francis Ltd, 2-4 Park Square, Milton Park, Abingdon, England.
  • NewsRx. Researchers' Work from Institute Jules Bordet Focuses on Cancer (Persistent Anti-tumor Response In Cancer Patients Experiencing Pneumonitis Related To Immune Checkpoint Blockade). Immunotherapy Weekly. April 21, 2021; p 4119.

Read more